NCT02827903

Brief Summary

Compare the Efficacy and Safety of Metformin/Rosuvastatin Combination Therapy With Metformin or Rosuvastatin Monotherapy in Patients With Type 2 Diabetes and Dyslipidemia

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
237

participants targeted

Target at P25-P50 for phase_3 type-2-diabetes

Timeline
Completed

Started Jan 2016

Typical duration for phase_3 type-2-diabetes

Geographic Reach
1 country

33 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 15, 2016

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

June 23, 2016

Completed
18 days until next milestone

First Posted

Study publicly available on registry

July 11, 2016

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 21, 2017

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 16, 2018

Completed
Last Updated

July 6, 2018

Status Verified

March 1, 2018

Enrollment Period

1.9 years

First QC Date

June 23, 2016

Last Update Submit

July 5, 2018

Conditions

Keywords

MetforminRosuvastatintype 2 diabetesdyslipidemia

Outcome Measures

Primary Outcomes (2)

  • LDL-C (% change)

    16 weeks from baseline

  • change of HbA1c

    16 weeks from baseline

Study Arms (3)

Group I

EXPERIMENTAL

Metformin + Rosuvastatin, Dosing to Type II DM with Dyslipidemia

Drug: Metformin + Rosuvastatin

Group II

ACTIVE COMPARATOR

Metformin + placebo, Dosing to Type II DM with Dyslipidemia

Drug: Metformin + placebo

Group III

ACTIVE COMPARATOR

Placebo + Rosuvastatin, Dosing to Type II DM with Dyslipidemia

Drug: placebo + Rosuvastatin

Interventions

Group I: Metformin + Rosuvastatin,

Group I

Group II: Metformin + placebo,

Group II

Group III: placebo + Rosuvastatin

Group III

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Over 19 years
  • Type II DM with Dyslipidemia
  • % ≤ HbA1c \< 11%
  • Triglyceride \< 350mg/dL
  • mg/dL ≤ LDL-C ≤ 250mg/dL
  • FPG ≤ 270mg/dL

You may not qualify if:

  • Type I DM
  • Unstable angina, MI, Stroke, CABG with 6 month from screening
  • SBP ≥ 180mmHg, DBP ≥ 110mmHg
  • TSH \> UNL
  • Heart failure (NYHA class III/IV)
  • Serum Creatinine \> UNL or CLCr \< 60 mL/min
  • CK ≥ 2x UNL
  • HIV positive
  • BMI \> 40 kg/m\^2

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (33)

Buchoen St. mary's Hospital

Bucheon-si, South Korea

Location

SeJong Hostpital

Bucheon-si, South Korea

Location

SoonChunHyang University Bucheon Hospital

Bucheon-si, South Korea

Location

InJe University Busan paik Hospital

Busan, South Korea

Location

Inje University Haeundae paik hospital

Busan, South Korea

Location

Daegu Catholic University Medical Center

Daegu, South Korea

Location

Youngnam University Hostpital

Daegu, South Korea

Location

Daeheon Eulji Medical Center

Daejeon, South Korea

Location

KonYang University Hostpital

Daejeon, South Korea

Location

Chosun University Hospital

Gwangju, South Korea

Location

BunDang Jesang Hospital(DMC)

Gyeonggi-do, South Korea

Location

Hallym University Sacred Heart hospital

Gyeonggi-do, South Korea

Location

HanYang University Guri Hospital

Gyeonggi-do, South Korea

Location

Inje University Ilsan paik hospital

Gyeonggi-do, South Korea

Location

Myoung Ji Hospital

Gyeonggi-do, South Korea

Location

Gachon Gil Hospital

Incheon, South Korea

Location

Inchoen St. mary's Hospital

Incheon, South Korea

Location

Eulji Hospital Nowon

Seoul, South Korea

Location

Hallym University Kangnam Sacred Heart hospital

Seoul, South Korea

Location

KangBuk SamSung Hospital

Seoul, South Korea

Location

Kangdong Sacred Heart Hospital

Seoul, South Korea

Location

KonKuk University Medical Center

Seoul, South Korea

Location

Korea University Anam Hospital

Seoul, South Korea

Location

KyungHee University Hospital at Gangdong

Seoul, South Korea

Location

Samsung Medical Center

Seoul, South Korea

Location

Seoul National University Hospital(Famlily medicine)

Seoul, South Korea

Location

Seoul National University Hospital

Seoul, South Korea

Location

Severance hospital

Seoul, South Korea

Location

SoonChunHayng University Hospital Seoul

Seoul, South Korea

Location

The catholic University of Korea YEOUIDO St mary's Hospital

Seoul, South Korea

Location

Korea University Guro hospital

Soeul, South Korea

Location

Ajou University hospital

Suwon, South Korea

Location

Wonju Severance Christian hospital

Wŏnju, South Korea

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Dyslipidemias

Interventions

MetforminRosuvastatin Calcium

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesLipid Metabolism Disorders

Intervention Hierarchy (Ancestors)

BiguanidesGuanidinesAmidinesOrganic ChemicalsSulfonamidesAmidesFluorobenzenesHydrocarbons, FluorinatedHydrocarbons, HalogenatedHydrocarbonsSulfonesSulfur CompoundsPyrimidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 23, 2016

First Posted

July 11, 2016

Study Start

January 15, 2016

Primary Completion

November 21, 2017

Study Completion

March 16, 2018

Last Updated

July 6, 2018

Record last verified: 2018-03

Data Sharing

IPD Sharing
Will not share

Locations